Published in Blood on June 01, 2015
The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis). Haematologica (2016) 0.80
Chromatin looping as a target for altering erythroid gene expression. Ann N Y Acad Sci (2016) 0.79
Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One (2015) 0.78
LSD1/KDM1A promotes hematopoietic commitment of hemangioblasts through downregulation of Etv2. Proc Natl Acad Sci U S A (2015) 0.78
Cellular normoxic biophysical markers of hydroxyurea treatment in sickle cell disease. Proc Natl Acad Sci U S A (2016) 0.77
New insights into sickle cell disease: mechanisms and investigational therapies. Curr Opin Hematol (2016) 0.77
LSD1: biologic roles and therapeutic targeting. Epigenomics (2016) 0.76
Cell signaling pathways involved in drug-mediated fetal hemoglobin induction: Strategies to treat sickle cell disease. Exp Biol Med (Maywood) (2015) 0.76
Heterochromatin Protein 1γ Is a Novel Epigenetic Repressor of Human Embryonic ϵ-Globin Gene Expression. J Biol Chem (2017) 0.75
Efficacy and Safety of Long-term RN-1 Treatment to Increase HbF in Baboons. Blood (2016) 0.75
Fetal Hemoglobin in Sickle Cell Anemia: The Arab-Indian Haplotype and New Therapeutic Agents. Am J Hematol (2017) 0.75
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
The serotonin syndrome. N Engl J Med (2005) 8.98
The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell (2007) 6.04
Sickle-cell disease. Lancet (2004) 4.76
Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat Struct Mol Biol (2007) 3.77
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
The beta-thalassemias. N Engl J Med (1999) 3.19
Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol (2006) 3.15
Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science (2011) 2.36
Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med (2013) 1.92
Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood (2006) 1.92
Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol (2002) 1.65
Genome-wide coactivation analysis of PGC-1alpha identifies BAF60a as a regulator of hepatic lipid metabolism. Cell Metab (2008) 1.65
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood (2011) 1.58
Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med (1988) 1.56
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood (1994) 1.56
Detrimental effects of adenosine signaling in sickle cell disease. Nat Med (2010) 1.54
LSD1 and the chemistry of histone demethylation. Curr Opin Chem Biol (2007) 1.52
Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A. Proc Natl Acad Sci U S A (2013) 1.50
2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood (2000) 1.43
Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol (2011) 1.42
Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program (2009) 1.40
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood (2002) 1.34
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood (1987) 1.27
Induction of gamma-globin by histone deacetylase inhibitors. Blood (1997) 1.26
Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res (2010) 1.24
FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure. Nat Commun (2012) 1.21
Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol (2009) 1.20
Hydroxyurea induces de novo copy number variants in human cells. Proc Natl Acad Sci U S A (2011) 1.17
P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol (2010) 1.17
Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea. N Engl J Med (1985) 1.16
Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood (1986) 1.08
In vitro erythropoiesis from bone marrow-derived progenitors provides a physiological assay for toxic and mutagenic compounds. Proc Natl Acad Sci U S A (2007) 1.07
Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem Neurosci (2011) 1.04
Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes. Proc Natl Acad Sci U S A (2011) 1.04
Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest (2014) 1.03
Structural and functional analysis of JMJD2D reveals molecular basis for site-specific demethylation among JMJD2 demethylases. Structure (2012) 1.00
Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol (2008) 0.99
Developmental transcriptome analysis of human erythropoiesis. Hum Mol Genet (2014) 0.99
DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res (2007) 0.98
Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer (2012) 0.93
Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol (2011) 0.89
Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J Clin Psychiatry (2012) 0.84
Pulsed-dosing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatr Blood Cancer (2008) 0.84
Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic β-type globin genes. Blood (2015) 0.84
Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol (2011) 0.83
PGC-1 coactivator activity is required for murine erythropoiesis. Mol Cell Biol (2014) 0.82
Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Eur J Haematol (2013) 0.80
Decitabine and sickle cell disease: molecular therapy for a molecular disease. Pediatr Hematol Oncol (2007) 0.76